Logo
Logo


ISSN: 0300-9041
ISSNe: 2594-2034


Indizada en: SciELO, Índice Médico Latinoamericano, LILACS, Medline
Editada por la Federación Mexicana de Colegios de Obstetricia, y Ginecologia AC
Fundada por la Asociación Mexicana de Ginecología y Obstetricia en 1945
 

INFORMACIÓN EXCLUSIVA PARA LOS PROFESIONALES DE LA SALUD


Periodicidad: continua
Abreviatura: Ginecol Obstet Mex
ISSN: 0300-9041
ISSNe: 2594-2034
Indizada en: Scimago, Índice Médico Latinoamericano, Lilacs, Medline, Science Citation Index, Ulrich, Ebsco.

Beneficios de los anticonceptivos orales combinados

Benefits of combined oral contraceptives.

Ginecol Obstet Mex. 2020;88(Supl 1):S47-S55.

https://doi.org/10.24245/gom.v88iSupl1.3849

David Vásquez-Awad

Ginecoobstetra, Perinatólogo, Epidemiólogo, Densitometrista; Clínico (ISCD) y Especialista en Seguridad Social. Miembro de número y Secretario General de la Academia Nacional de Medicina de Colombia. Miembro del Consejo de la Facultad de Medicina de la Pontificia Universidad Javeriana de Bogotá, DC, Colombia. Expresidente y Miembro Honorario de la Asociación Colombiana de Menopausia. Experto latinoamericano en Menopausia y Climaterio FLASCYM. Fellow American College of Obstetricians and Gynecologists


Debe citarse como:

Vásquez-Awad D. Beneficios de los anticonceptivos orales combinados. Ginecol Obstet Mex. 2020;88(Supl 1):S47-S55. https://doi.org/10.24245/gom.v88iSupl1.3849

Resumen

Después de 40 años, los anticonceptivos orales combinados han mostrado un perfil de seguridad óptimo que permite indicarlos a distintos grupos etarios. En años recientes se ha observado que, a la par del efecto anticonceptivo para el que fueron creados, los hormonales orales combinados ofrecen diversos efectos benéficos, ginecológicos o no, que se han estudiado con detenimiento. El propósito de este artículo es analizar, a la luz de la evidencia, los efectos benéficos no anticonceptivos de los hormonales orales combinados en mujeres no interesadas en planificar su familia. Los anticonceptivos orales combinados repercuten positivamente en la vida de las mujeres en edad reproductiva, no solo desde el punto de vista médico sino en el ámbito social, emocional, antropológico, económico y de autoestima. El control de la fertilidad ha sido uno de los avances más notorios en la lucha –que es de todos los ginecólogos– por lograr la igualdad de género. Además de los efectos anticonceptivos de los hormonales orales combinados, también son reconocidos los beneficios ginecológicos y no ginecológico de estos fármacos.

PALABRAS CLAVE: Anticonceptivos orales combinados; beneficios; ginecológicos; fertilidad.

Abstract

After 40 years, combined oral contraceptives have shown an optimal safety profile that allows to indicate them to different age groups. In recent years it has been observed that, along with the contraceptive effect for which they were created, combined oral hormones offer various beneficial effects, gynecological or not, that have been studied carefully. The purpose of this article is to analyze, in the light of the evidence, the beneficial non-contraceptive effects of combined oral hormones in women not interested in planning her family. Combined oral contraceptives have a positive impact on the life of women in reproductive age, not only from a medical point of view, but also in the social, emotional, anthropological, economic and self-esteem fields. The control of fertility has been one of the most notorious advances in the struggle –which belongs to all gynecologists– to achieve gender equality. In addition to the contraceptive effects of combined oral hormones, the gynecological and non-gynecological benefits of these drugs are also recognized.

KEYWORDS: Combined oral contraceptives; Benefits; Gynecological; Fertility.

    1. Huxley A. Brave new world revisited. New York: Harper and Row, 1958:138-139. https://archive.org/stream/Brave_New_World_Revisited/Brave%20New%20World%20Revisited%20-%20Huxley%20%281958%29_djvu.txt
    2. Peterson HB, et al. The health effects of oral contraceptives: Misperceptions, controversies, and continuing good news. Clin Obstet Gynecol 1989;32:339-355.
    3. Panser LA, et al. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception 1991;43:91-9. https://doi.org/10.1016/0010-7824(91)90130-8
    4. van Hoof MH, et al. The use of oral contraceptives by adolescents for contraception, menstrual cycle problems or acne. Acta Obstet Gynecol Scand 1998;77(9):898-904. https://doi.org/10.1034/j.1600-0412.1998.770905.x
    5. Sundell G, et al. Factors influencing the prevalence and severity of dysmenorrhea in young women. Br J Obstet Gynaecol 1990;97:588-594. https://doi.org/10.1111/j.1471-0528.1990.tb02545.x
    6. Lanes SF, et al. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992;166:956-961. https://doi.org/10.1016/0002-9378(92)91371-G
    7. Ross RK, et al. Risk factors for uterine fibroids: Reduced risk associated with oral contraceptives. BMJ (Clin Res Ed) 1986;293(6543):359-362. https://www.bmj.com/content/bmj/293/6543/359.full.pdf
    8. Chiaffarino F, et al. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynecol 1999;106:857-860. https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1471-0528.1999.tb08409.x
    9. Cancer and Steroid Hormone Study of the Center for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 1987;316:650-655. https://www.nejm.org/doi/full/10.1056/NEJM198703123161102
    10. Hankinson SE, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992;80:708-714.
    11. Narod SA, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428.
    12. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined ral contraceptives: A practitioner´s guide to meta-analysis. Hum Reprod 1997;12:1851-1863.
    13. Sherman ME, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 10:963-968,1997.
    14. Vessey M, et al. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006;95:385-389. https://www.nature.com/articles/6603260
    15. Parazzini F, et al. Contraceptive methods and risk of pelvic endometriosis. Contraception 1994;49:47-55
    16. Moore J, et al. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 1999;3:3. http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD001019/full
    17. Martínez ME, et al. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1997;6:1-5. http://cebp.aacrjournals.org/content/6/1/1.full-text.pdf
    18. Franceschi S, et al. Oral contraceptives and colorectal tumors: A review of epidemiologis studies. Contraception 1998;58:335-343. https://doi.org/10.1016/S0010-7824(98)00128-0
    19. Milman N, et al. Iron status in 268 Danish women aged 18-30 years: Influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998;77(1-2):13-19. https://link.springer.com/article/10.1007/s002770050405
    20. Lucky AW, et al. Effectiveness of norgestimate and ethynil estradiol in treating moderates acne vulgaris. J Am Acad Dermatol 1997;37(5 pt 1):746-54. https://doi.org/10.1016/S0190-9622(97)70112-9
    21. Redmond GP, et al. Norgestimate and ethynil estradiol in the treatment of acne vulgaris: A randomized , placebo-controlled trial. Obstet Gynecol 1997;89:615-622. https://doi.org/10.1016/S0029-7844(97)00059-8
    22. Gambacciani M, et al. Longitudinal evaluation of perimenopausal vertebral bone loss: Effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol 1994;83:392-396.
    23. Kleerekoper M, et al. Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group. Arch Intern Med 1991;151:1971-1976.
    24. Michaelsson K, et al. Oral contraceptive use and risk of hip fracture: A case-control study. Lancet 1999;353(9163):1481-1484. https://doi.org/10.1016/S0140-6736(98)09044-8
    25. Brinton LA, et al. Risk factors for benign breast disease. Am J Epidemiol 1981;113:203-214. https://doi.org/10.1093/oxfordjournals.aje.a113089
    26. Brennan P, et al. Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin Arthritis Rheum 1997;26:817-823. https://www.semarthritisrheumatism.com/article/S0049-0172(97)80025-X/pdf
    27. Burkman R, et al. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004;190(4)(S1). https://doi.org/10.1016/j.ajog.2004.01.061

Comentarios